Skip to main content
Premium Trial:

Request an Annual Quote

Helicos BioSciences' Q4 Revenues Plummet to $514,000

NEW YORK (GenomeWeb News) – Helicos BioSciences disclosed after the close of the market on Friday it recorded $514,000 in revenues for the fourth quarter, down nearly five-fold from $2.5 million in the year-ago period.

The company, which recently said that it may be forced to cease operations if it is unable to obtain additional funding, said in its full-year 2011 earnings document filed with the US Securities and Exchange Commission on Friday that product revenues plummented to $117,000 during the quarter from $960,000 a year ago, while service revenues increased to $153,000 from zero. Grant revenues were down to $244,000 from $1.6 million a year ago.

Helicos' R&D costs rose to $2.3 million from $840,000 a year ago, while SG&A spending slid to $947,000 from $1.4 million.

The Cambridge, Mass.-based firm posted a net loss of $2.9 million, or $.03 per share, during the quarter, compared to a profit of $1.2 million, or $.01 per share, a year ago.

Helicos recorded $3.2 million in revenues for full-year 2011, down 38 percent from $4.4 million in 2010, as product revenues dropped to $571,000 from $1.3 million a year ago.

The company posted service revenues of $1.2 million, compared to none a year ago, but grant revenues were down to $1.5 million from $3.1 million in 2010.

Its R&D spending was cut to $4.9 million from $14.0 million, and the firm cut its SG&A costs to $4.1 million from $10.5 million in 2010.

Helicos' net loss for 2011 improved to $5.8 million, or $.07 per share, from a net loss of $18.8 million, or $.24 per share, a year ago.

The company ended 2011 with roughly $1 million in cash and cash equivalents.

In an SEC filing in early March, the firm said that it then had about $200,000 in cash and cash equivalents. Recently its CEO Ivan Trifunovich became the president and CEO of WaferGen Biosystems. He remains Helicos' president CEO on a part-time basis, as he had done in the prior six months.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.